Navigation Links
AfriCoLeish receives funding boost from European Union
Date:4/22/2013

[Geneva, Switzerland and Nairobi, Kenya 23 April 2013] - Research and development (R&D) project, AfriCoLeish, is supported by the European Union Seventh Framework Programme (EU FP7) through a grant of 3 million. The project will run for three years and aims to test new treatments for kala-azar (visceral leishmaniasis, or VL) and co-infection of the disease with HIV in Ethiopia and Sudan.

The AfricoLeish project, 'Care Package for Treatment and Control of Visceral Leishmaniasis in East Africa', aims to develop and deliver a shorter combination treatment for kala-azar patients that is equally as safe and effective as the current WHO-recommended first-line treatment for the disease (SSG&PM, sodium stibogluconate and paromomycin) in East Africa. The project also aims to determine appropriate treatment strategies for kala-azar in patients that are also HIV positive, in order to treat and also prevent repetitive relapses that are common in co-infected patients.

Kala-azar (VL) is fatal if left untreated. An estimated 300,000 cases occur per year in 70 endemic countries. Estimates suggest 30,000 new cases per year in Africa, with numbers rising sharply during an epidemic. Existing monotherapies are toxic, costly, and difficult to administer, and the treatment duration is long, requiring extended hospital stays. Efficacious and cost-effective treatments as well as prevention of relapse play a critical role in the reduction of disease reservoir, forming a vital part of disease control. In addition, co-infection of kala-azar and HIV is a growing problem and renders treatment more difficult for both diseases.

'While we have managed to deliver a new first-line treatment for kala-azar in East Africa, sodium stibogluconate combined with paromomycin, SSG&PM, we need to continue searching for shorter, safer treatments', said Dr Monique Wasunna, Head of DNDi Africa and one of the four principal investigators of the AfriCoLeish project. 'Through a rand
'/>"/>

Contact: Violaine Dällenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Hasbro Childrens Hospital physician receives $3.2 million grant to study teen alcohol use
2. AmeriPride Minneapolis Receives ‘Hygienically Clean Healthcare’ Certification from the Textile Rental Services Association (TRSA)
3. Dr. Sam Speron Receives the 2012 America’s Most Compassionate Doctor Award
4. Morelli receives AACR fellowship for research in metastatic colorectal cancer
5. Christopher Jayne, M.D., Receives InTone Specialist Certification To Treat Female Urinary Incontinence From InControl Medical, LLC
6. Local Female Clinical Research Executive Receives Industry Distinction as an Innovator for Change
7. Tosh Patterson Receives Honors at the 5th Annual Get RADICAL Women’s Conference Featuring Jillian Michaels, Lisa Nichols, Giuliana Rancic
8. Vincent R. Lucente, MD, MBA, Miles Murphy, MD, Nina Bhatia, MD, and Valerie Schissler, MSN, CRNP, Receives InTone Specialist Certification
9. Advanced Mold Diagnostics Receives Angie's List Super Service Award for 4th Straight Year
10. BU student receives 2013 Joanna M. Nicolay Melanoma Foundation scholarship award
11. UC Davis MIND Institute receives prestigious Autism Centers of Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Cook For Your Life (CFYL), a New ... to people touched by cancer, is launching its first ... by founder Ann Ogden, will be facilitated by Drexel ... partnership will expand the program from its base. , ... After going through her own cancer treatments, Ogden realized ...
(Date:3/4/2015)... growing influence of movies, television, video games and the internet ... with the increasingly frantic lifestyle of modern parents, it can ... what kids are into these days. It seems that every ... , The same is also true for drugs and alcohol. ... talk about them, are constantly changing. These tips put a ...
(Date:3/4/2015)... Surrey, BC (PRWEB) March 04, 2015 ... will perform LASIK and PRK procedures at their new ... Vision Correction, Dr. Joseph King and Dr. Gabriel Chu ... ophthalmology practice in Surrey is named Fraser Valley Cataract ... facility is accredited by the College of Physicians and ...
(Date:3/4/2015)... NY (PRWEB) March 04, 2015 The ... centerfold of The San Francisco Chronicle with a circulation ... 500,000 readers. Its digital component is distributed nationally through ... of top news sites and partner outlets. To explore ... , Milorganite is composed of heat-dried microbes ...
(Date:3/4/2015)... Texas (PRWEB) March 04, 2015 ... , Endometriosis can be a painful condition ... starts spreading outside of the uterus leading to very ... their families. Endometriosis can have a terrible effect on ... It is also the most common cause of infertility ...
Breaking Medicine News(10 mins):Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:King LASIK relocates to Surrey, British Columbia 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3
... a discovery that may well be giving HIV health care workers ... men having a highly drug resistant form of HIV in King ... rapidly than others and is likewise more difficult to treat. ... present in the four men, all gay, who are also methamphetamine ...
... the Intensive Care Unit (ICU) and family members of ... and depression in the family members, according to a ... of the New England Journal of Medicine. ... Institute of Nursing Research (NINR), a component of the ...
... impairment that strikes in the early stages of prion diseases such ... ,The findings suggest there may be a way to cure ... before it has time to kill off large numbers of brain ... lives of 158 people in Britain, and seven more are known ...
... women’s menstrual cycles affect the responsiveness of their brains’ ... of// Mental Health (NIMH), a component of the National ... ,While women were winning rewards, their circuitry was more ... ovulation and dominated by estrogen, compared to a phase ...
... genes from an ancient wheat variety have led to a ... a recent set of papers published in the journal Plant ... and Nax2. The genes work by excluding salt from different ... from the leaves. The discovery of the two genes is ...
... grant product patent for Glivec, the cancer drug from Novartis ... not be able to conduct// their drug research here in ... its research now. ,While talking ... of Novartis reveals that this decision by the Indian government ...
Cached Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:Researchers Make Strides in VCJD Detection 2Health News:NIMH Studies Woman’s Hormonal Cycl 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2
(Date:3/4/2015)... , March 4, 2015  Hill-Rom Holdings, Inc. ... Stacy Enxing Seng has been elected to its ... Executive in Residence for Covidien, as well as President ... President of Peripheral Vascular from 2010 to 2012. ... the $2.6B acquisition of ev3 Incorporated, where she was ...
(Date:3/4/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... Phase II proof of concept clinical study investigating ... monotherapy in the treatment of chronic pruritus in ... and clinically meaningful improvement from baseline by tradipitant ... a 100mm unit Visual Analog Scale (VAS) for ...
(Date:3/4/2015)... NEW YORK , March 4, 2015 /PRNewswire/ ... orthopedic device market is the increasing elderly population, ... in a recent report from the healthcare market ... aging population coupled with other risk factors such ... orthopedic incidence worldwide. Demand for innovative product designs ...
Breaking Medicine Technology:Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3
... , , , , ... Inc. (Nasdaq: RIGL ) today announced that in the ... had failed to respond to at least one biologic treatment, the ... ACR 20, ACR 50, ACR 70 and DAS28 response rates than ...
... , G rowth ... for cardiac stem cells , ... regrow, but researchers at Children,s Hospital Boston have now laid the groundwork for ... in children with congenital heart defects. In the July 24 issue of ...
Cached Medicine Technology:R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 2R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 4R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 5R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 6R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 7R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 8Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3
... stents that save inventory, shelf space, and ... lengths from 22 cm to 28 cm. ... to glide over any guidewire and through ... ease of placement and patient comfort in ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection....
The Shandon Sequenza uses the Shandon Coverplate system which ensures consistency and excellent staining quality. , , ,Allows the user to perform large immunostaining runs (up to 50 slides/run...
Medicine Products: